Voximetry

Voximetry, Inc. operates as a commercial-stage healthcare technology firm with a focus on personalizing cancer treatment. Founded in 2016, the company is a spin-off from the University of Wisconsin-Madison and is headquartered in Madison, Wisconsin. The founding team includes Joseph Grudzinski, PhD, Bryan Bednarz, PhD, and Paul Wickre, MS, who bring together deep expertise in medical physics, radiopharmaceuticals, and commercial software development for radiation oncology. Dr. Grudzinski first conceptualized a treatment planning system for radiopharmaceutical therapy as a graduate student in 2009. His subsequent experience at Philips Radiation Oncology Systems and Cellectar, LLC, combined with Dr. Bednarz's academic research in medical physics and Mr. Wickre's 20 years in commercializing radiation treatment software, laid the groundwork for Voximetry.

The company targets the rapidly expanding Radiopharmaceutical Therapy (RPT) market, which serves over 350,000 patients annually in the U.S. for cancers including prostate, lymphoma, thyroid, liver, and neuroendocrine tumors. Voximetry's business model is twofold, generating revenue through a Software-as-a-Service (SaaS) subscription for its flagship product, Torch®, and by providing professional dosimetry services directly to clinicians and pharmaceutical companies conducting clinical trials. This dual approach allows clinicians to either use the software themselves or outsource the complex analysis to Voximetry's expert team at its "Vox Lab". The company has secured significant funding through Small Business Innovation Research (SBIR) grants from the National Institutes of Health and a Pre-A funding round with participation from the Wisconsin Alumni Research Foundation (WARF).

Voximetry's core offering is Torch®, an FDA-cleared software platform for dosimetry-guided RPT. The system addresses a critical flaw in current RPT practices, which typically rely on one-size-fits-all dosing. Torch® leverages high-speed Graphics Processing Units (GPUs) to analyze patient-specific nuclear medicine scans (SPECT/CT) and performs voxel-level dosimetry using Monte Carlo radiation transport calculations. This process creates a detailed, 3D assessment of how a specific radiopharmaceutical will distribute throughout a patient's body, calculating the precise radiation dose to both tumors and healthy organs. The platform automates complex tasks like image registration and pharmacokinetic modeling, providing clinicians with an accurate imaging biomarker to personalize treatment plans, which can lead to better patient outcomes. By delivering these highly accurate dose assessments in minutes, Torch® aims to make personalized radiation therapy a standard of care.

Keywords: radiopharmaceutical therapy, dosimetry, oncology, medical imaging software, personalized medicine, cancer treatment, treatment planning, SaaS, clinical trials, healthtech